Treace Medical Concepts (TMCI) Expected to Announce Quarterly Earnings on Friday

Treace Medical Concepts (NASDAQ:TMCI) is projected to post its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $44.02 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.

Treace Medical Concepts (NASDAQ:TMCI) last posted its earnings results on Friday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. The business had revenue of $47.20 million for the quarter, compared to analyst estimates of $45.96 million. On average, analysts expect Treace Medical Concepts to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Treace Medical Concepts Stock Performance

NASDAQ TMCI opened at $4.78 on Thursday. The company’s 50 day simple moving average is $4.13 and its two-hundred day simple moving average is $2.72. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.58 and a quick ratio of 2.53. Treace Medical Concepts has a 1 year low of $1.17 and a 1 year high of $7.78. The stock has a market capitalization of $310.08 million, a PE ratio of -4.93 and a beta of 1.37.

Analysts Set New Price Targets

TMCI has been the topic of several research analyst reports. Weiss Ratings raised shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Truist Financial lifted their price objective on Treace Medical Concepts from $2.00 to $4.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Finally, Wall Street Zen upgraded Treace Medical Concepts from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Treace Medical Concepts presently has a consensus rating of “Reduce” and a consensus target price of $4.97.

Insider Buying and Selling

In related news, CEO John T. Treace purchased 61,750 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was acquired at an average price of $2.62 per share, with a total value of $161,785.00. Following the purchase, the chief executive officer directly owned 7,158,313 shares in the company, valued at approximately $18,754,780.06. This represents a 0.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have purchased 371,600 shares of company stock valued at $1,104,801. 23.42% of the stock is owned by insiders.

Institutional Trading of Treace Medical Concepts

Hedge funds have recently made changes to their positions in the stock. Kotler Kevin purchased a new position in shares of Treace Medical Concepts in the 4th quarter worth about $1,162,000. Paradigm Capital Management Inc. NY purchased a new position in shares of Treace Medical Concepts during the 2nd quarter valued at about $1,577,000. Millennium Management LLC raised its holdings in shares of Treace Medical Concepts by 12.7% during the 3rd quarter. Millennium Management LLC now owns 1,710,140 shares of the company’s stock valued at $11,475,000 after buying an additional 192,929 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Treace Medical Concepts during the 4th quarter valued at about $380,000. Finally, Moore Capital Management LP bought a new stake in Treace Medical Concepts in the 3rd quarter worth approximately $990,000. 84.08% of the stock is owned by institutional investors.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.